SCHEMBL2812477

SCHEMBL2812477

CON=C(C(=O)O)c1ccco1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.52
CES1 P23141 1/20 0.52
PTPN1 P18031 1/20 0.52
SMN1; SMN2 Q16637 7/20 0.47
TDP1 Q9NUW8 3/20 0.47
PKM P14618 3/20 0.45
ERCC5 P28715 1/20 0.45
FEN1 P39748 1/20 0.45
RAB9A P51151 5/20 0.43
NPC1 O15118 4/20 0.43
POLB P06746 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
KMT2A Q03164 3/20 0.43
MEN1 O00255 1/20 0.42
ALDH1A1 P00352 1/20 0.42
THRB P10828 1/20 0.42
APEX1 P27695 1/20 0.42
RECQL P46063 1/20 0.42
MAOB P27338 2/20 0.41
TP53 P04637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11457463 1.00 CES2 (0.52) CES2CES1PTPN1SMN1; SMN2TDP1
SCHEMBL4609969 1.00 CES2 (0.52) CES2CES1PTPN1SMN1; SMN2TDP1
Ammonia Solution, Strong SCHEMBL4752940 0.98 CES2 (0.50) CES2CES1PTPN1SMN1; SMN2TDP1
Ammonia Solution, Strong SCHEMBL5211578 0.98 CES2 (0.50) CES2CES1PTPN1SMN1; SMN2TDP1
Ammonia Solution, Strong SCHEMBL28417876 0.98 CES2 (0.50) CES2CES1PTPN1SMN1; SMN2TDP1
SCHEMBL13983961 0.86 CES2 (0.52) CES2CES1PTPN1SMN1; SMN2TDP1
SCHEMBL5217865 0.85 CES2 (0.50) CES2CES1PTPN1SMN1; SMN2TDP1
SCHEMBL12180935 0.85 CES2 (0.50) CES2CES1PTPN1SMN1; SMN2TDP1
SCHEMBL9634783 0.85 CES2 (0.55) CES2CES1PTPN1SMN1; SMN2TDP1
SCHEMBL17426488 0.85 CES2 (0.50) CES2CES1PTPN1SMN1; SMN2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120025299-A Synthesis method of (Z) -2-methoxyimino-2-furyl ammonium acetate 河南立诺制药有限公司 2025-05-23 CN claimed
CN-118561788-A Methoxyiminofuran acetic acid cis-trans isomerism conversion method 河南立诺制药有限公司 2024-08-30 CN claimed
CN-113999194-B Process for the preparation of furan ammonium salts 山东金城医药化工有限公司 2023-09-12 CN claimed
CN-113999194-A Process for the preparation of furan ammonium salts 山东金城医药化工有限公司 2022-02-01 CN claimed
CN-111440196-A Method for nickel-based catalytic synthesis of 3-decarbamoyl cefuroxime acid 山东金城柯瑞化学有限公司 2020-07-24 CN claimed
CN-102070572-B Method for recovering and preparing furanone acid from syn-2-methoxyimino-2-(2-furayl)-acetic acid-ammonia salt waste residue SHANDONG JINCHENG PHARMACEUTICAL & CHEMICAL CO LTD 2012-10-03 CN claimed
CN-102070572-A Method for recovering and preparing furanone acid from syn-2-methoxyimino-2-(2-furayl)-acetic acid-ammonia salt waste residue SHANDONG JINCHENG PHARMACEUTICAL & CHEMICAL CO LTD 2011-05-25 CN claimed
EP-1319009-B1 INTERMEDIATES IN CEPHALOSPORIN PRODUCTION SANDOZ AG (CH) 2008-10-22 EP claimed
US-6894162-B2 Intermediates in cephalosporin production SANDOZ GMBH (AT) 2005-05-17 US claimed
CN-1200941-C Intermediates in cephalosporing production BIOCHEMIE GMBH (AT) 2005-05-11 CN claimed
WO-2004050663-A2 AN IMPROVED PROCESS FOR THE PREPARATION OF CEFUROXIME SODIUM ORCHID CHEMICALS & PHARMACEUTICALS LTD (IN) 2004-06-17 WO claimed
WO-2004041831-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF CEFUROXIME SODIUM ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) 2004-05-21 WO claimed
US-20040092735-A1 Process for the preparation of cefuroxime sodium ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) 2004-05-13 US claimed
CN-1454212-A Intermediates in cephalosporing production BIOCHEMIE GMBH (AT) 2003-11-05 CN claimed
US-20030171577-A1 Intermediates in cephalosporin production SANDOZ GMBH (FORMERLY BIOCHEMIE GMBH) (AT) 2003-09-11 US claimed
EP-1319009-A1 INTERMEDIATES IN CEPHALOSPORIN PRODUCTION BIOCHEMIE GESELLSCHAFT M.B.H. (AT) 2003-06-18 EP claimed
WO-2002020532-A1 INTERMEDIATES IN CEPHALOSPORIN PRODUCTION BIOCHEMIE GESELLSCHAFT M.B.H. (AT) 2002-03-14 WO claimed
US-4876351-A Process for the separation of a mixture of \"syn\" and \"anti\" oxime isomers GLAXO GROUP LIMITED (GB) 1989-10-24 US claimed
JP-56133293-A None JP disclosed
US-4103085-A CEPHALOSPORIN ANTIBIOTICS BRISTOL-MYERS COMPANY (US) 1978-07-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092735-A1 Process for the preparation of cefuroxime sodium CYP2F1, CYP51A1, CYP17A1 CES2 1088/4885CES1 113/4885PTPN1 1363/4885
US-20030171577-A1 Intermediates in cephalosporin production BBOX1, SLC6A12, BCHE CES2 55/4885CES1 665/4885PTPN1 3801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.